Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:12:37.049Z.
Calculation as of: 2026-10-06T15:12:37.049Z.
Quote observation: 2026-10-06T15:10:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 243952859d49b374df7eb324c8bbcd7e4caeb894f26e22f2834818a88b726353
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-03-28.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.95B
EV/FCF Ratio
742.38x
TTM Avg
495.80x
3Y Avg
11749.41x
5Y Avg
11749.41x
Market Cap
$1.95B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.99B
EV/FCF Ratio
16.18x
TTM Avg
20.29x
3Y Avg
742.45x
5Y Avg
860.87x
Market Cap
$2.02B
EV/FCF Ratio
10.96x
TTM Avg
15.23x
3Y Avg
21.85x
5Y Avg
21.85x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.97B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 742.38x | 495.80x | 11749.41x | 11749.41x |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.95B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | 16.18x | 20.29x | 742.45x | 860.87x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 10.96x | 15.23x | 21.85x | 21.85x |
| Azenta, Inc. (AZTA)vs › | $1.91B | 179.33x | 49.00x | 83.04x | 82.00x |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.03B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 8.73x | 10.18x | 12.16x | 63.65x |
| Novavax, Inc. (NVAX)vs › | $1.90B | N/A | 19.57x | 82.87x | 82.87x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 6.43x | 31.04x | 48.35x | 48.35x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2024-03-28 | 79.46x |
| 2024-03-27 | 83.32x |
| 2024-03-26 | 82.72x |
| 2024-03-25 | 76.33x |
| 2024-03-22 | 77.80x |
| 2024-03-21 | 76.98x |
| 2024-03-20 | 76.88x |
| 2024-03-19 | 76.70x |
| 2024-03-18 | 67.60x |
| 2024-03-15 | 69.34x |
| 2024-03-14 | 69.16x |
| 2024-03-13 | 74.95x |
| 2024-03-12 | 77.90x |
| 2024-03-11 | 74.72x |
| 2024-03-08 | 88.38x |
| 2024-03-07 | 91.69x |
| 2024-03-06 | 87.09x |
| 2024-03-05 | 81.71x |
| 2024-03-04 | 79.73x |
| 2024-03-01 | 83.00x |
| 2024-02-29 | 77.25x |
| 2024-02-28 | 78.45x |
| 2024-02-27 | 85.53x |
| 2024-02-26 | 80.10x |
| 2024-02-23 | 74.54x |
| 2024-02-22 | 72.88x |
| 2024-02-21 | 67.18x |
| 2024-02-20 | 71.73x |
| 2024-02-16 | 84.79x |
| 2024-02-15 | 69.53x |
| 2024-02-14 | 65.94x |
| 2024-02-13 | 68.93x |
| 2024-02-12 | 73.80x |
| 2024-02-09 | 72.24x |
| 2024-02-08 | 73.99x |
| 2024-02-07 | 80.56x |
| 2024-02-06 | 72.24x |
| 2024-02-05 | 43.60x |
| 2024-02-02 | 40.88x |
| 2024-02-01 | 41.62x |
| 2024-01-31 | 42.17x |
| 2024-01-30 | 51.04x |
| 2024-01-29 | 54.72x |
| 2024-01-26 | 46.36x |
| 2024-01-25 | 41.39x |
| 2024-01-24 | 36.42x |
| 2024-01-23 | 34.91x |
| 2024-01-22 | 37.94x |
| 2024-01-19 | 28.06x |
| 2024-01-18 | 27.96x |
| 2024-01-17 | 30.36x |
| 2024-01-16 | 30.03x |
| 2024-01-12 | 26.49x |
| 2024-01-11 | 20.93x |
| 2024-01-10 | 21.16x |
| 2024-01-09 | 21.16x |
| 2024-01-08 | 21.16x |
| 2024-01-05 | 17.11x |
| 2024-01-04 | 19.04x |
| 2024-01-03 | 20.29x |
| 2024-01-02 | 16.61x |
| 2023-12-29 | 15.18x |
| 2023-12-28 | 15.32x |
| 2023-12-27 | 13.71x |
| 2023-12-26 | 12.70x |
| 2023-12-22 | 9.16x |
| 2023-12-21 | 4.42x |
| 2023-12-20 | 3.92x |
| 2023-12-19 | 3.37x |
| 2023-12-18 | 1.62x |
| 2023-12-15 | 0.65x |
| 2023-12-08 | 1.53x |
| 2023-12-07 | 1.39x |
| 2023-12-06 | 2.03x |
| 2023-12-05 | 1.90x |
| 2023-12-04 | 2.68x |
| 2023-12-01 | 1.85x |
| 2023-11-30 | 0.29x |
| 2023-11-29 | 0.47x |
| 2023-11-28 | 1.25x |
| 2023-11-27 | 2.40x |
| 2023-11-24 | 2.77x |
| 2023-11-22 | 2.49x |
| 2023-11-21 | 2.54x |
| 2023-11-20 | 1.80x |
| 2023-11-17 | 2.72x |
| 2023-11-16 | 2.45x |
| 2023-11-15 | 2.54x |
| 2023-11-14 | 2.86x |
| 2023-11-13 | 3.87x |
| 2023-11-10 | 3.18x |
| 2023-11-09 | 17.81x |
| 2023-11-08 | 18.59x |
| 2023-11-07 | 18.95x |
| 2023-11-06 | 18.53x |
| 2023-11-03 | 18.43x |
| 2023-11-02 | 18.30x |
| 2023-11-01 | 17.84x |
| 2023-10-31 | 18.59x |
| 2023-10-30 | 18.59x |
| 2023-10-27 | 18.37x |
| 2023-10-26 | 18.73x |
| 2023-10-25 | 18.99x |
| 2023-10-24 | 19.18x |
| 2023-10-23 | 17.97x |
| 2023-10-20 | 18.37x |
| 2023-10-19 | 16.70x |
| 2023-10-18 | 17.94x |
| 2023-10-17 | 18.43x |
| 2023-10-16 | 18.99x |
| 2023-10-13 | 19.22x |
| 2023-10-12 | 17.22x |
| 2023-10-11 | 15.36x |
| 2023-10-10 | 15.20x |
| 2023-10-09 | 15.49x |
| 2023-10-06 | 15.03x |
| 2023-10-05 | 14.38x |
| 2023-10-04 | 14.71x |
| 2023-10-03 | 15.82x |
| 2023-10-02 | 16.63x |
| 2023-09-29 | 17.12x |
| 2023-09-28 | 16.27x |
| 2023-09-27 | 14.51x |
| 2023-09-26 | 13.92x |
| 2023-09-25 | 12.78x |
| 2023-09-22 | 13.48x |
| 2023-09-21 | 13.43x |
| 2023-09-20 | 13.11x |
| 2023-09-19 | 13.56x |
| 2023-09-18 | 13.73x |
| 2023-09-15 | 13.56x |
| 2023-09-14 | 14.28x |
| 2023-09-13 | 13.82x |
| 2023-09-12 | 14.18x |
| 2023-09-11 | 15.36x |
| 2023-09-08 | 14.25x |
| 2023-09-07 | 12.75x |
| 2023-09-06 | 10.00x |
| 2023-09-05 | 11.60x |
| 2023-09-01 | 11.21x |
| 2023-08-31 | 10.92x |
| 2023-08-30 | 10.33x |
| 2023-08-29 | 10.36x |
| 2023-08-28 | 10.13x |
| 2023-08-25 | 10.29x |
| 2023-08-24 | 12.81x |
| 2023-08-23 | 13.02x |
| 2023-08-22 | 12.78x |
| 2023-08-21 | 12.97x |
| 2023-08-18 | 12.94x |
| 2023-08-17 | 12.71x |
| 2023-08-16 | 13.69x |
| 2023-08-15 | 14.18x |
| 2023-08-14 | 13.14x |
| 2023-08-11 | 13.58x |
| 2023-08-10 | 12.88x |
| 2023-08-09 | 27.52x |
| 2023-08-08 | 28.73x |
| 2023-08-07 | 29.25x |
| 2023-08-04 | 29.37x |
| 2023-08-03 | 28.81x |
| 2023-08-02 | 28.00x |
| 2023-08-01 | 29.21x |
| 2023-07-31 | 28.48x |
| 2023-07-28 | 30.90x |
| 2023-07-27 | 28.16x |
| 2023-07-26 | 30.42x |
| 2023-07-25 | 27.52x |
| 2023-07-24 | 29.37x |
| 2023-07-21 | 28.16x |
| 2023-07-20 | 29.61x |
| 2023-07-19 | 32.68x |
| 2023-07-18 | 33.24x |
| 2023-07-17 | 33.40x |
| 2023-07-14 | 33.40x |
| 2023-07-13 | 35.01x |
| 2023-07-12 | 38.16x |
| 2023-07-11 | 40.82x |
| 2023-07-10 | 36.87x |
| 2023-07-07 | 43.08x |
| 2023-07-06 | 44.61x |
| 2023-07-05 | 40.09x |
| 2023-07-03 | 35.34x |
| 2023-06-30 | 34.53x |
| 2023-06-29 | 32.84x |
| 2023-06-28 | 18.41x |
| 2023-06-27 | 16.31x |
| 2023-06-26 | 13.89x |
| 2023-06-23 | 15.66x |
| 2023-06-22 | 13.89x |
| 2023-06-21 | 16.55x |
| 2023-06-20 | 16.55x |
| 2023-06-16 | 17.44x |
| 2023-06-15 | 13.81x |
| 2023-06-14 | 13.33x |
| 2023-06-13 | 12.60x |
| 2023-06-12 | 10.83x |
| 2023-06-09 | 9.05x |
| 2023-06-08 | 9.78x |
| 2023-06-07 | 10.91x |
| 2023-06-06 | 10.50x |
| 2023-06-05 | 12.36x |
| 2023-06-02 | 13.33x |
| 2023-06-01 | 14.45x |
| 2023-05-31 | 13.00x |
| 2023-05-30 | 12.04x |
| 2023-05-26 | 12.04x |
| 2023-05-25 | 13.41x |
| 2023-05-24 | 16.95x |
| 2023-05-23 | 16.63x |
| 2023-05-22 | 11.87x |
| 2023-05-19 | 15.62x |
| 2023-05-18 | 14.62x |
| 2023-05-17 | 16.47x |
| 2023-05-16 | 16.79x |
| 2023-05-15 | 20.90x |
| 2023-05-12 | 25.82x |
| 2023-05-11 | 22.03x |
| 2023-05-10 | 21.55x |
| 2023-05-09 | 21.15x |
| 2023-05-08 | 17.20x |
